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Background: We investigated the impact of follow-up duration to determine whether two immunohistochemical prognostic
panels, IHC4 and Mammostrat, provide information on the risk of early or late distant recurrence using the Edinburgh Breast
Conservation Series and the Tamoxifen vs Exemestane Adjuvant Multinational (TEAM) trial.
Methods: The multivariable fractional polynomial time (MFPT) algorithm was used to determine which variables had possible non-
proportional effects. The performance of the scores was assessed at various lengths of follow-up and Cox regression modelling
was performed over the intervals of 0–5 years and 45 years.
Results: We observed a strong time dependence of both the IHC4 and Mammostrat scores, with their effects decreasing over
time. In the first 5 years of follow-up only, the addition of both scores to clinical factors provided statistically significant information
(Po0.05), with increases in R2 between 5 and 6% and increases in D-statistic between 0.16 and 0.21.
Conclusions: Our analyses confirm that the IHC4 and Mammostrat scores are strong prognostic factors for time to distant
recurrence but this is restricted to the first 5 years after diagnosis. This provides evidence for their combined use to predict early
recurrence events in order to select those patients who may/will benefit from adjuvant chemotherapy.
Prediction of residual risk following adjuvant endocrine treatment in
early breast cancer has become a critical component in the selection
of treatment options. In addition, recent data on the impact of up to
10 years of adjuvant endocrine therapy in early breast cancer suggest
that some women may benefit from extended treatment with
tamoxifen(Goss et al, 2003; Davies et al, 2013; Gray et al, 2013). At
present, patients and their clinicians may be presented with three
time-related choices related to the treatment of luminal breast
cancers: (1) whether it is beneficial to treat patients with adjuvant
chemotherapy and therefore delay endocrine therapy; (2) whether to
follow a switch strategy for endocrine therapy; and (3) whether to
extend endocrine therapy after 5 years for a total of 10 years.
Multiple diagnostic algorithms have been developed to provide
information on residual risk for patients facing these choices;
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however, there is limited information on how time impacts the risk
assessments provided by these diagnostic tools.
A recent study developed a residual risk model (IHC4; Cuzick
et al, 2011) combining immunohistochemical (IHC) assessment of
ER, PgR, Ki67 and HER2, which provided equivalent information
on residual risk to the multiparameter, PCR-based, OncotypeDx
test. The IHC4þC (IHC markers plus clinicopathologic para-
meters) score also provides additional information on the residual
risk of distant recurrence to ER-positive primary breast cancer
patients receiving adjuvant endocrine therapy, supplementary to
that provided by the Adjuvant online! and NPI intermediate-risk
groups (Barton et al, 2012). Another IHC model (Mammostrat;
Ring et al, 2006) has been developed combining five IHC
biomarkers (p53, NDRG1,CEACAM5, SLC7A5 and HTF9C),
which has been shown to significantly improve traditional
prognostic factors in predicting outcome for ER-positive breast
cancer patients (Ross et al, 2008; Bartlett et al, 2010, 2012).
Non-proportional effects of prognostic scores have been
previously reported with better prediction for patients at high risk
of early relapse rather than for those at risk of later recurrent
disease (Buyse et al, 2006; Desmedt et al, 2007; Haibe-Kains et al,
2008). Haibe-Kains et al (2008) suggested that this could be due to
three reasons: (i) different biological mechanisms for the
occurrence of early and late relapses; (ii) the statistical methodol-
ogy, with the scores being developed on cohorts based on median
follow-up; (iii) the quality of survival data, where one could
intuitively believe that the quality of survival data decreases with
respect to the duration of follow-up as it is difficult to follow up
patients during a long period resulting in a high level of censoring.
In this study we investigated the impact of follow-up duration
on the IHC4 and Mammostrat scores to determine whether these
two prognostic panels provide information on the risk of early or
late recurrence.
MATERIALS AND METHODS
Materials. The Edinburgh Breast Conservation Series (BCS)
represents a fully documented, consecutive cohort of 1812 patients
treated by breast conservation surgery, axillary node sampling or
clearance, and whole breast radiotherapy at the Edinburgh Cancer
Centre between 1981 and 1998 (Thomas et al, 2009; Bartlett et al,
2010). Following ethical approval (Lothian Local Research Ethics
04) tissue blocks were retrieved from all cases and sufficient
material was available from 1686 cases for assembly into tissue
microarrays (TMAs) (Supplementary Figure 1A). For all cases with
available tissue, tumours were regraded on whole sections by a
single pathologist (Thomas et al, 2009).
The Tamoxifen Exemestane Adjuvant Multinational (TEAM)
trial is a multinational randomised, open-label, phase III trial in
postmenopausal women with hormone receptor-positive early
breast cancer testing the efficacy of 5 years of exemestane (25mg
once per day) vs tamoxifen (20mg once per day for 2.5–3 years)
followed by exemestane for a total of 5 years (van de Velde et al,
2011). Five of nine participating countries provided paraffin-
embedded tumour samples for pathology sub-studies (Bartlett et al,
2011a). Tissue blocks were received at a central laboratory and
4598 were found suitable for TMA construction (Supplementary
Figure 1B).
Biomarker analysis. Immunohistochemical staining for a panel of
biomarkers including ER, PgR, HER2, Ki67, HTF9C, CEACAM5,
NDRG1, p53 and SLC7A5 and FISH (fluorescence in situ
hybridisation) for HER2 was performed using either sextuplet
(ER and PgR) or triplicate (all other markers) 0.6mm2 TMA cores.
Results were derived from dual scoring by expert observers
(as described by Kirkegaard et al (2006)) for the Edinburgh BCS
cohort for all markers. For TEAM patients, ER, PgR and Ki67
scores were derived by quantitative image analysis using the Ariol
system with algorithms validated against both whole sections and
manual assessment (Faratian et al, 2009; Bartlett et al, 2011a). Data
for ER were recorded as a histoscore (Kirkegaard et al, 2006) and
for Ki67 and PgR as a percentage of positive cells (ATAC and Ki67
guidelines; Dowsett et al, 2011). Results for HER2 were scored
according to the UK guidelines (Walker et al, 2008; Bartlett et al,
2011b), with cases regarded as HER2-amplified if any core showed
amplification/overexpression. Positivity for p53, HTF9C (recently
re-named TRIMT2A), CEACAM5, NDRG1 and SLC7A5 was
recorded as previously described (Ring et al, 2006; Ross et al, 2008;
Bartlett et al, 2010, 2012).
Generation of prognostic scores. The IHC4 model (Cuzick et al,
2011) utilised a linear combination of multiple markers: ER, PgR,
HER2 and Ki67. Continuous marker scores were normalised prior
to inclusion in the IHC4 model. ER histoscores were divided by 30,
and PgR scores as a percentage of cells staining positive were
divided by 10 to obtain continuous values between 0 and 10. Ki67
scores were represented as percentage positive cells and HER2 was
treated as a dichotomous variable. The IHC4 risk score was
generated according to the previously specified algorithm (Cuzick
et al, 2011). The IHC4 score is analysed as a continuous risk score,
except for Kaplan–Meier analyses, in which the IHC4 score is
categorised into three groups using two cutoff points that
correspond to a 10-year distant recurrence rate of 10% and 20%
from the original study; however, these cutoffs have not been
previously validated (Cuzick et al, 2011).
The Mammostrat model (Ring et al, 2006) used five IHC
markers: SLC7A5, CEACAM5, NDRG1, HTF9C and p53. The
Mammostrat risk score was generated by combining binary
staining results for all markers as either positive or negative
according to the previously specified algorithm (Ring et al, 2006;
Ross et al, 2008; Bartlett et al, 2010, 2012). The Mammostrat score
was categorised into low (p0), medium (40 and o0.7) and high
(X0.7) risk categories as previously specified (Ring et al, 2006;
Ross et al, 2008; Bartlett et al, 2010, 2012).
Missing data. The known technical limitations of TMAs inevi-
tably result in missing data (Voduc et al, 2008). A large amount of
data were missing (32.1%) for the PgR variable measured as a
percentage of positive cells in the Edinburgh BCS cohort.
Therefore, multiple imputation was performed using all predictors
plus the event indicator and the Nelson–Aalen estimator of the
cumulative baseline hazard, as recommended by White and
Royston (2009). We used the mi impute chained command in
Stata to perform multiple imputation using chained equations to
generate 42 imputed data sets, based on the rule of thumb
suggested by White et al (2011). The results from analyses on each
of the imputed data sets were combined using Rubin’s rules to
produce estimates and confidence intervals that incorporate the
uncertainty of imputed values (Rubin, 1987).
Statistical analysis. The primary end point selected for this study
was time to distant recurrence (TTDR) as this is the event that
drives subsequent death from breast cancer. Time to distant
recurrence was defined as the time to distant metastasis (van de
Velde et al, 2011) or death with evidence of recurrent breast cancer,
with patients censored at the time of last follow-up. Additional
clinical variables used, when specified, were age (continuous),
tumour size (continuous), number of positive nodes (continuous),
histological grade (grade I–III), treatment (exemestane/tamoxifen
in TEAM) and chemotherapy (yes/no). Investigation into the
functional form of continuous covariates on the log-hazard
identified tumour size and the number of positive nodes to be
non-linear and were included as such in all analyses.
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The primary analysis was based on ER-positive patients treated
with endocrine therapy (without chemotherapy). Secondary
analyses were performed on all ER-positive patients irrespective
of treatment. Exploratory analyses were performed on node-
negative and node-positive ER-positive patients treated with
endocrine therapy (without chemotherapy) and on node-positive
ER-positive patients irrespective of treatment.
The assumption of proportional hazards when performing Cox
regression was tested by plotting scaled Schoenfeld residuals
against time and testing for a zero slope. Cox modelling was
performed including a covariate–log (time) interaction into the
model. The multivariable fractional polynomial time (MFPT)
algorithm proposed by Sauerbrei et al (2007) was used to
determine which variables had possible non-proportional effects,
as well as the best-fitting fractional polynomial to model these
effects. We explored the effect of these derived risk scores before
and after 5 years (as a decision point for continued endocrine
therapy at this time) to determine whether either score provided
information on the residual risk of early or late distant recurrence.
The performance of the IHC4 and Mammostrat risk scores was
assessed along with conventional clinical risk factors using
measures of calibration and discrimination, with follow-up
censored at 5, 9 and 15 years for the Edinburgh BCS cohort and
3 and 5 years for the TEAM cohort. ‘Model calibration’ refers to
how closely the estimates of survival from the model agree with the
survival from the observed data (Altman et al, 2009; Moons et al,
2009). This was assessed for each decile of predicted risk, ensuring
10 equally sized groups, by producing a calibration plot (observed
vs predicted probabilities of 5-year distant recurrence) and
calculating the calibration slope. ‘Discrimination’ is the ability of
a risk score to differentiate between patients who do and those who
do not experience an event during the study period (McGeechan
et al, 2008; Altman et al, 2009). Discrimination was evaluated using
Royston and Sauerbrei’s (2004) R2 statistic based on their index of
discrimination (D), with a difference in D of at least 0.1 indicating
improved prognostic separation. All statistical analyses were
carried out in Stata (version 12).
RESULTS
Data were available on 1449 (ER-negative and ER-positive)
patients with 273 distant recurrences from the Edinburgh BCS
cohort (median follow-up of 12.9 years) and on 3766 (ER-positive)
patients with 548 distant recurrences from the TEAM cohort
(median follow-up of 6.2 years). The distributions of the scores
were different between the two cohorts (Supplementary Figure 2),
with the median IHC4 scores being 44 and 27 in the Edinburgh
BCS and TEAM cohorts, respectively. A larger proportion of
patients (64%) were allocated to the low Mammostrat risk group in
the Edinburgh BCS cohort compared with 43% in the TEAM
cohort. This is as expected because of the TEAM cohort being a
higher-risk population compared with the Edinburgh BCS cohort,
with higher mean tumour size (23mm vs 16mm, respectively), a
larger proportion of higher grade tumours (grade 3: 35% vs 19%,
respectively) and higher mean number of positive nodes (1.9 vs 0.5,
respectively).
Non-proportional effects in a multivariable model. In multi-
variable modelling, the MFPT algorithm determined IHC4 to have
a significant time-by-covariate interaction for both patient
subgroups in both cohorts with the best-fitting FP to be log of
time. The parameter associated with this interaction was negative,
suggesting the effect of a unit increase in IHC4 on TTDR decreased
over time (Figure 1). The decrease over time was more prominent
in the Edinburgh BCS cohort, with the adjusted HR crossing the
value 1 (corresponding to a null effect) at approximately 6.5 years.
The Mammostrat score was determined to have a significant time-
by-covariate interaction in the Edinburgh BCS cohort only for high
risk vs low risk (Figure 2). There was uncertainty in the best-fitting
FP to model the interaction, with log of time chosen for all
ER-positive patients and time-cubed chosen for ER-positive
patients treated with endocrine therapy only.
Impact of follow-up duration on model performance. We
assessed the performance of the scores in addition to clinical
factors at various lengths of follow-up. Measures of discrimination
are given in Table 1 for full follow-up (using all available data
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Figure 1. Time-dependent adjusted hazard ratio estimate (up to 10
years) with 95% CIs (dashed lines) for a unit increase in IHC4 score for
all ER-positive patients in (A) the Edinburgh BCS cohort and (B) the
TEAM cohort. Adjusted for age, grade, nodes positive, treatment and
chemotherapy.
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Figure 2. Time-dependent adjusted hazard ratio estimate with 95%
CIs (dashed lines) for high-risk compared with low-risk Mammostrat
score in the Edinburgh BCS cohort for (A) all ER-positive patients and
(B) ER-positive patients treated with endocrine therapy only. Adjusted
for age, grade, nodes positive, treatment and chemotherapy.
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rather than censoring at a specific time point) and follow-up
censored at 5 years. In the Edinburgh BCS cohort the models
performed statistically better with shorter follow-up compared
with full follow-up with differences in D-statistic between 0.4 and
0.5 and R2 between 7 and 13%. There was a small improvement in
model performance with shorter follow-up in the TEAM cohort,
with increases in R2 between 1.5 and 3% and differences in
D-statistic between 0.05 and 1. The calibration of the combined
model was improved in the Edinburgh BCS cohort with follow-up
censored at 5 years, with a calibration slope estimate of 1.0 (95% CI
0.8–1.1) for follow-up censored at 5 years vs 1.2 (0.8–1.5) for full
follow-up for all ER-positive patients.
Prognostic value of scores within the first 5 years and beyond
5 years after diagnosis. To investigate whether either score
provided prognostic information on TTDR beyond 5 years after
diagnosis, Cox regression was performed with follow-up time
divided into the intervals 0–5 years and 5–10 years. Period-specific
Kaplan–Meier curves are displayed in Supplementary Figure 3.
Both scores were significant independent predictors of outcome
restricted to the first 5 years of follow-up, after which there was no
evidence that the scores were associated with TTDR (Table 2). For
example, the interquartile HR for IHC4 score was 2.1 (95% CI,
1.1–4.1) in the first 5 years after diagnosis compared with 1.0 (95%
CI, 0.5–2.0) after 5 years for all ER-positive patients in the
Table 1. Performance data on IHC4 and Mammostrat score in addition to clinical factors
All ER-positive ER-positive endocrine only
Model % R2 (95 % CI) D-Statistic (95% CI) % R2 (95 % CI) D-Statistic (95% CI)
Edinburgh BCS
Full follow-up
Clinical 24.0 (16.2–31.7) 1.15 (0.91–1.39) 25.7 (16.7–34.6) 1.20 (0.92–1.48)
IHC4 24.4 (16.7–32.1) 1.16 (0.92–1.41) 26.3 (17.4–35.1) 1.22 (0.94–1.50)
Mammostrat 25.4 (17.6–33.2) 1.19 (0.95–1.44) 27.1 (18.1–36.1) 1.25 (0.97–1.53)
Combined 25.7 (18.0–33.5) 1.21 (0.96–1.45) 27.9 (19.0–36.8) 1.27 (0.99–1.56)
5 Years
Clinical 31.1 (20.8–41.4) 1.51 (1.17–1.85) 35.3 (23.3–47.4) 1.51 (1.12–1.91)
IHC4 33.7 (23.6–43.8) 1.63 (1.28–1.98) 39.0 (27.2–50.7) 1.63 (1.23–2.04)
Mammostrat 33.6 (23.4–43.8) 1.58 (1.23–1.92) 38.5 (26.8–50.3) 1.62 (1.22–2.02)
Combined 36.5 (26.4–46.5) 1.69 (1.34–2.04) 41.3 (29.9–52.7) 1.72 (1.31–2.12)
TEAM
Full follow-up
Clinical 27.5 (23.00–32.0) 1.26 (1.12–1.40) 29.5 (23.6–35.3) 1.33 (1.14–1.51)
IHC4 31.0 (26.5–35.4) 1.37 (1.23–1.52) 32.8 (27.0–38.4) 1.43 (1.24–1.62)
Mammostrat 29.8 (25.3–34.2) 1.33 (1.19–1.48) 31.0 (25.1–36.7) 1.37 (1.18–1.56)
Combined 32.3 (27.8–36.7) 1.41 (1.27–1.56) 33.3 (27.5–38.9) 1.45 (1.26–1.63)
5 Years
Clinical 29.0 (23.8–34.1) 1.31 (1.14–1.47) 30.5 (23.7–37.0) 1.36 (1.14–1.57)
IHC4 34.0 (28.9–38.9) 1.47 (1.31–1.63) 34.9 (28.3–41.2) 1.50 (0.29–1.71)
Mammostrat 31.5 (26.4–36.5) 1.39 (1.23–1.55) 32.2 (25.5–38.6) 1.41 (1.20–1.62)
Combined 35.4 (30.3–40.2) 1.51 (1.35–1.68) 35.5 (28.9–41.7) 1.52 (1.31–1.73)
Abbreviations: BCS¼breast conservation series; CI¼ confidence interval; ER¼ estrogen receptor; IHC¼ immunohistochemical; IHC4¼ IHC4 score. NOTE: Measures of discrimination for
patients in the Edinburgh BCS and TEAM cohorts with full follow-up and follow-up censored at 5 years. A difference in D of at least 0.1 indicates improved prognostic separation. The models
being assessed are: clinical factors, age, grade, tumour size, nodes positive, treatment and chemotherapy; IHC4, IHC4 in addition to clinical factors; Mammostrat, Mammostrat in addition to
clinical factors; Combined, IHC4 and Mammostrat in addition to clinical factors.
Table 2. Period-specific multivariate Cox regression of IHC4 and Mammostrat score
All ER-positive ER-positive endocrine only
0–5 years 5–10 years 0–5 Years 5–10 years
Main effecta HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Edinburgh BCS
(97 events) (61 events) (70 events) (45 events)
IHC4 2.09 (1.07–4.05) 1.02 (0.53–1.96) 1.79 (0.87–3.71) 1.20 (0.59–2.44)
MvL 1.84 (1.14–2.97) 1.50 (0.80–2.80) 2.00 (1.13–3.54) 1.50 (0.72–3.13)
HvL 1.65 (0.94–2.92) 1.36 (0.65–2.85) 1.87 (0.98–3.57) 1.68 (0.75–3.77)
TEAM
(416 events) (132 events) (242 events) (74 events)
IHC4 1.69 (1.18–2.44) 1.21 (0.70–2.07) 1.34 (0.85–2.10) 0.89 (0.44–1.78)
MvL 1.44 (1.09–1.90) 1.38 (0.86–2.21) 1.41 (0.98–2.01) 0.96 (0.51–1.81)
HvL 2.01 (1.56–2.60) 1.57 (1.02–2.44) 1.72 (1.24–2.38) 1.18 (0.69–2.04)
Abbreviations: BCS¼breast conservation series; CI¼ confidence interval; HvL¼ high v low risk Mammostrat score; IHC¼ immunohistochemical; IHC4¼ IHC4 score; MvL¼ medium v low risk
Mammostrat score. NOTE: Separate multivariate analysis of IHC4 and Mammostrat scores with conventional histopathologic variables for TTDR before 5 years and after 5 years for patients in
different subgroups. Values represent estimated hazard ratios and 95% CIs calculated as between the IQR of the continuous IHC4 score and high and medium risk compared with low risk as
categorised by the Mammostrat score for all patients with ER-positive breast cancer and ER-positive patients who received no chemotherapy in the Edinburgh BCS and TEAM cohorts.
aAdjusted for age, grade, tumour size, nodes positive, treatment and chemo.
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Edinburgh BCS cohort. There was evidence of a prognostic effect
after 5 years for Mammostrat high risk vs low risk for all
ER-positive patients (Table 2) and ER-positive node-negative
patients treated with endocrine therapy (Supplementary Table 1)
in the TEAM cohort with HRs of 1.6 (95% CI, 1.0–2.4) and 3.3
(95% CI, 1.1–10.5), respectively. This effect of Mammostrat high vs
low risk was also seen in the Edinburgh BCS cohort for ER-positive
node-negative patients treated with endocrine therapy only
(Supplementary Table 1) for the 5–10-year time period after
diagnosis with an HR of 2.8 (95% CI, 1.0–7.8).
Comparison of IHC4 and Mammostrat. The IHC4 score provided
additional prognostic information beyond that of clinical factors
compared with the Mammostrat score for all ER-positive patients
in both patient cohorts in the first 5 years of follow-up
(Supplementary Table 2; increase in R2: 6.6% vs 2.5% and
D-statistic: 0.12 vs 0.07 in the Edinburgh BCS cohort and increase
in R2: 5.0% vs 2.5% and D-statistic: 0.16 vs 0.08 in the TEAM
cohort). Similarly, for ER-positive patients treated with endocrine
therapy in the TEAM cohort, the IHC4 score was the stronger
predictor of outcome, whereas in the Edinburgh cohort the
prognostic information provided by either score was similar
(increase in R2: 3.7% vs 3.2% and D-statistic: 0.12 vs 0.11).
The addition of both scores to clinical factors. The scores were
entered simultaneously into a multivariate Cox regression model,
and in the first 5 years of follow-up the addition of both scores to
clinical factors provided statistically significant information
(Po0.05) for both subsets of patients across both cohorts with
increases in R2 between 5 and 6% and increases in D-statistic
between 0.16 and 0.21 (Supplementary Table 2). However, both
scores only remained significant independent predictors of TTDR
restricted to the first 5 years of follow-up when simultaneously
entered into a multivariate Cox regression model for all ER-
positive patients in the TEAM cohort with an interquartile HR for
ICH4 score of 1.6 (95% CI, 1.1–2.4) and HRs for medium and high
vs low Mammostrat score of 1.3 (95% CI, 1.0–1.8) and 1.7 (95% CI,
1.3–2.2), respectively (Supplementary Tables 3). Only the IHC4
score provided significant independent prognostic information on
TTDR in the first 5 years of follow-up for all ER-positive patients
treated with endocrine therapy in the TEAM cohort and for both
patient subgroups in the Edinburgh BCS cohort. Although not
statistically significant, the Mammostrat score provided some
improvement in model discrimination over and above that
provided by the IHC4 score and clinical factors with an increase
in R2 and D-statistic of 2.3% and 0.09, respectively, for ER-positive
patients treated with endocrine therapy only in the Edinburgh BCS
cohort. There was evidence of an effect of Mammostrat high risk vs
low risk after 5 years of survival after adjustment for IHC4 and
clinical factors in ER-positive, node-negative patients treated with
endocrine therapy only in the TEAM and Edinburgh BCS cohorts
with HRs of 3.2 (95% CI, 1.0–10.1) and 2.8 (95% CI, 1.0–7.7),
respectively (Supplementary Table 4).
DISCUSSION
Our analyses confirm that the IHC4 and Mammostrat scores are
strong prognostic predictors for TTDR, but this is restricted to the
first 5 years after diagnosis. The prognostic effect of IHC4 and
Mammostrat score on TTDR decreased with increasing follow-up
time. A previous analysis by Sgroi et al (2013) also confirmed a
significant prognostic ability for IHC4 for early distant recurrence
only (0–5 years).
The performance of both scores was good, especially in the first
5 years of follow-up, with the combination of both scores
significantly improving the ability to discriminate between events
and non-events when compared with clinical factors only and good
calibration between observed and predicted 5-year risk of TTDR.
The IHC4 score provided more prognostic information on TTDR
compared with the Mammostrat score in the first 5 years of follow-
up except for all ER-positive patients in the larger TEAM cohort
where the addition of both scores provided statistically significant
information.
Despite the effects of the scores being strongest in the first 5
years after diagnosis, there was evidence of a prognostic effect of
the Mammostrat score with respect to the risk of late recurrence
(beyond 5 years after diagnosis). ER-positive, node-negative
patients treated with endocrine therapy only who were classified
as having a high-risk Mammostrat score had 2.8 (95% CI, 1.0–7.8)
and 3.3 (95% CI, 1.1–10.5) times the risk for distant recurrence
after 5 years compared with those classified as havng low risk in
the Edinburgh BCS and TEAM cohorts, respectively. These results
suggest the possible use of Mammostrat score to predict the risk of
late recurrence, which will need to be investigated further on other
patient cohorts with long-term follow-up.
Missing data were present, although the majority of patients had
information on all risk factors. We used current recommended
approaches with multiple imputation to overcome the biases that
occur when performing complete-case analysis (Burton and
Altman, 2004; Vergouwe et al, 2010).
The IHC4 is analysed as a continuous score, but for Kaplan–
Meier analysis cutoff points are required. To avoid the biases that
occur from choosing our own cutoff points, we used those from the
original study (Cuzick et al, 2011). However, these did not validate
well in our cohorts, allocating only a small number of patients to
the low-risk group (o10%).
In conclusion, the IHC4 and Mammostrat risk scores were
significantly associated with risk for distant disease recurrence in
the first 5 years after diagnosis and added prognostic information
beyond that provided by clinical factors. Mammostrat may provide
insights to patients and clinicians seeking to make informed
decision about extended endocrine therapy after an initial 5 years
of treatment and warrants further study.
CONFLICT OF INTEREST
JMSB has received travel support and speakers fees from GE
Healthcare (who market Mammostrat). The remaining authors
declare no conflict of interest.
REFERENCES
Altman DG, Vergouwe Y, Royston P, Moons KGM (2009) Prognosis and
prognostic research: validating a prognostic model. Br Med J 338: b605.
Bartlett JMS, Bloom KJ, Piper T, Lawton TJ, van de Velde CJH, Ross DT,
Ring BZ, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H,
Markopoulos C, Dirix L, Seynaeve C, Rea D (2012) Mammostrat as an
immunohistochemical multigene assay for prediction of early relapse risk
in the tamoxifen versus exemestane adjuvant multicenter trial pathology
study. J Clin Oncol 30(36): 4477–4484.
Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ,
Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback DG,
Putter H, Markopoulos C, Kranenbarg EM-K, Mallon EA, Dirix L,
Seynaeve C, Rea D (2011a) Estrogen receptor and progesterone receptor as
predictive biomarkers of response to endocrine therapy: a prospectively
powered pathology study in the tamoxifen and exemestane adjuvant
multinational trial. J Clin Oncol 29(12): 1531–1538.
Bartlett JMS, Starczynski J, Atkey N, Kay E, O’Grady A, Gandy M, Ibrahim M,
Jasani B, Ellis IO, Pinder SE, Walker RA (2011b) HER2 testing in the UK:
recommendations for breast and gastric in-situ hybridisation methods.
J Clin Pathol 64(8): 649–653.
BRITISH JOURNAL OF CANCER Relapse risk in early breast cancer
2246 www.bjcancer.com |DOI:10.1038/bjc.2014.530
Bartlett JMS, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC,
Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L,
Cameron DA, Chetty U (2010) Mammostrat (R) as a tool to stratify breast
cancer patients at risk of recurrence during endocrine therapy. Breast
Cancer Res 12(4): R47.
Barton S, Zabaglo L, A’Hern R, Turner N, Ferguson T, O’Neill S, Hills M,
Smith I, Dowsett M (2012) Assessment of the contribution of the
IHC4þC score to decision making in clinical practice in early breast
cancer. Br J Cancer 106(11): 1760–1765.
Burton A, Altman DG (2004) Missing covariate data within cancer prognostic
studies: a review of current reporting and proposed guidelines. Br J Cancer
91(1): 4–8.
Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, d’Assignies MS,
Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A,
Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ,
Consortium T (2006) Validation and clinical utility of a 70-gene
prognostic signature for women with node-negative breast cancer.
J Natl Cancer Inst 98(17): 1183–1192.
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E,
Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic
value of a combined estrogen receptor, progesterone receptor, Ki-67, and
human epidermal growth factor receptor 2 immunohistochemical score
and comparison with the genomic health recurrence score in early breast
cancer. J Clin Oncol 29(32): 4273–4278.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M,
Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M,
Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M,
Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Mittra I, Mueller B,
Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R,
Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R.
Adjuvant Tamoxifen Longer A (2013) Long-term effects of continuing
adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis
of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Lancet 381(9869): 805–816.
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G,
Delorenzi M, Zhang Y, D’Assignies MS, Bergh J, Lidereau R, Ellis P,
Harris AL, Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M,
Sotiriou C (2007) Strong time dependence of the 76-gene prognostic
signature for node-negative breast cancer patients in the TRANSBIG
multicenter independent validation series. Clinical Cancer Research
13(11): 3207–3214.
Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M,
Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F,
Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA,
Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations
from the international Ki67 in breast cancer working group. J Natl Cancer
Inst 103(22): 1656–1664.
Faratian D, Munro A, Twelves C, Bartlett JMS (2009) Membranous and
cytoplasmic staining of Ki67 is associated with HER2 and ER status in
invasive breast carcinoma. Histopathology 54(2): 254–257.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M,
Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE,
Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A
randomized trial of letrozole in postmenopausal women after five years
of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):
1793–1802.
Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T
(2013) aTTom: Long-term effects of continuing adjuvant tamoxifen to 10
years versus stopping at 5 years in 6,953 women with early breast cancer.
In 2013 ASCO Annual Meeting.
Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, van’t Veer L,
Piccart M, Bontempi G, Sotiriou C (2008) Comparison of prognostic gene
expression signatures for breast cancer. BMC Genomics 9: 394.
Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R,
Tam L, Munro AF, Dunne B, Bartlett JMS (2006) Observer variation in
immunohistochemical analysis of protein expression, time for a change?
Histopathology 48(7): 787–794.
McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY (2008) Assessing new
biomarkers and predictive models for use in clinical practice a clinician’s
guide. Arch Intern Med 168(21): 2304–2310.
Moons KGM, Altman DG, Vergouwe Y, Royston P (2009) Prognosis and
prognostic research: application and impact of prognostic models in
clinical practice. Br Med J 338: b606.
Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MCU,
Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT (2006)
Novel prognostic immunohistochemical biomarker panel for
estrogen receptor-positive breast cancer. J Clin Oncol 24(19):
3039–3047.
Ross DT, Kim C-y, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS,
Paik S, Costantino JP, Wolmark N (2008) Chemosensitivity and
stratification by a five monoclonal antibody immunohistochemistry
test in the NSABP B14 and B20 trials. Clini Cancer Res 14(20):
6602–6609.
Royston P, Sauerbrei W (2004) A new measure of prognostic separation in
survival data. Stat Med 23(5): 723–748.
Rubin D (1987) Multiple imputation for nonresponse in surveys. Wiley.
Sauerbrei W, Royston P, Look M (2007) A new proposal for multivariable
modelling of time-varying effects in survival data based on fractional
polynomial time-transformation. Biom J 49(3): 453–473.
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG,
Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M (2013)
Prediction of late distant recurrence in patients with oestrogen-receptor-
positive breast cancer: a prospective comparison of the breast-cancer index
(BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study
population. Lancet Oncol 14(11): 1067–1076.
Thomas JSJ, Kerr GR, Jack WJL, Campbell F, McKay L, Pedersen H-C,
Kunkler IH, Cameron DA, Chetty U, Bartlett JMS (2009) Histological
grading of invasive breast carcinoma-a simplification of existing methods
in a large conservation series with long-term follow-up. Histopathology
55(6): 724–731.
van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J-M,
Paridaens R, Markopoulos C, Hozumi Y, Hille ETM, Kieback DG,
Asmar L, Smeets J, Nortier JWR, Hadji P, Bartlett JMS, Jones SE (2011)
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM):
a randomised phase 3 trial. Lancet 377(9762): 321–331.
Vergouwe Y, Royston P, Moons KGM, Altman DG (2010) Development and
validation of a prediction model with missing predictor data: a practical
approach. J Clin Epidemiol 63(2): 205–214.
Voduc D, Kenney C, Nielsen TO (2008) Tissue Microarrays in clinical
oncology. Seminars in Radiation Oncology 18(2): 89–97.
Walker RA, Bartlett JMS, Dowsett M, Ellis IO, Hanby AM, Jasani B, Miller K,
Pinder SE (2008) HER2 testing in the UK: further update to
recommendations. J Clin Pathol 61(7): 818–824.
White IR, Royston P (2009) Imputing missing covariate values for the Cox
model. Stat Med 28(15): 1982–1998.
White IR, Royston P, Wood AM (2011) Multiple imputation using
chained equations: Issues and guidance for practice. Stat Med 30(4):
377–399.
StataCorp (2011) Stata Statistical Software: Release 12. StataCorp LP: College
Station, TX.
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Relapse risk in early breast cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.530 2247
